Copyright © Inderes 2011 - present. All rights reserved.

Nexstim

14.10 EUR

-0.70 %

5,595 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

-0.70 %
-4.73 %
+11.02 %
+38.24 %
+78.48 %
+114.94 %
+223.39 %
+169.59 %
-97.67 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
101.71M EUR
Turnover
50.15K EUR
P/E (adj.) (25e)
24.96
EV/EBIT (adj.) (25e)
24.28
P/B (25e)
12.9
EV/S (25e)
6.58
Dividend yield-% (25e)
-
Coverage
Recommendation
Reduce
Target price
12.50 EUR
Updated
18.08.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 18.08.2025

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
It looks like it’s going down to the wire again, but that’s how it went last year too:
12/4/2025, 7:37 AM
by Kyhnykeisari
23
Google searches for transcranial magnetic stimulation have almost doubled in Q3/2025 vs Q3/2024. These are not actual search volumes, but indexed and compiled at a quarterly level. The original data can be found here: https://trends.google.com/trends/explore?date=today%205-y\u0026q...
12/8/2025, 7:34 AM
by Kyhnykeisari
16
Sinaptican funding round progresses: Sinaptica Therapeutics™ - Noninvasive Neuromodulation: A True Breakthrough in... – 11 Dec 25 Sinaptica Therapeutics Receives Funding from The Centre for Aging + Brain... Cambridge, MA – December 10, 2025 – Sinaptica Therapeutics, Inc., a clinical...
8 hours ago
by Tim89
10
I still live in the belief that those would also be announced. What would be Nexstim’s interest in keeping such a positive surprise under wraps? I stick to my position that a significant Brainlab deal will only start next year and will largely follow the previously stated 18-month...
12/9/2025, 4:51 PM
by Kyhnykeisari
9
2023 also went down to the wire. Hopefully, with Brainlab, this seasonality would even out at least a little. It’s certainly difficult to change hospitals’ spending habits, but it’s quite exciting business this way!
12/5/2025, 8:56 AM
by Kyhnykeisari
9
Sometimes as a child, I was disappointed with the scout calendar when it didn’t contain chocolate. This calendar has been even more useless so far, but hopefully, by next week at the latest, more interesting doors will start to appear!
12/9/2025, 3:34 PM
by Kyhnykeisari
8
2025’s Grand Finale: Inside the Best of Keiretsu Forum Virtual Investment Showcase linkedin.com 2025’s Grand Finale: Inside the Best of Keiretsu Forum Virtual Investment... In the final weeks of 2025, the US early-stage investment community turned its attention to one place: the ...
3 hours ago
by Jatast
7
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.